Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 21:8:627957.
doi: 10.3389/fped.2020.627957. eCollection 2020.

Lower CMV and EBV Exposure in Children With Kawasaki Disease Suggests an Under-Challenged Immune System

Affiliations

Lower CMV and EBV Exposure in Children With Kawasaki Disease Suggests an Under-Challenged Immune System

Diana van Stijn et al. Front Pediatr. .

Erratum in

Abstract

Background: Kawasaki Disease (KD) is a pediatric vasculitis of which the pathogenesis is unclear. The hypothesis is that genetically pre-disposed children develop KD when they encounter a pathogen which remains most often unidentified or pathogen derived factors. Since age is a dominant factor, prior immune status in children could influence their reactivity and hence the acquisition of KD. We hypothesized that systemic immune responses early in life could protect against developing KD. With this study we tested whether the incidence of previous systemic cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection is lower in children with KD compared to healthy age-matched controls. Methods and Results: We compared 86 KD patients with an age-matched control group regarding CMV and EBV VCA IgG measurements (taken before or 9 months after IVIG treatment). We found that both CMV and EBV had an almost 2-fold lower seroprevalence in the KD population than in the control group. Conclusions: We suggest that an under-challenged immune system causes an altered immune reactivity which may affect the response to a pathological trigger causing KD in susceptible children.

Keywords: Epstein-Barr virus; Kawasaki disease; cytomegalovirus; immune system; viral exposure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Patient selection. *Chosen time frame was 9 months after IVIG treatment but not later than 2 years after onset of disease.
Figure 2
Figure 2
(A) % of CMV seropositivity. (B) % of EBV seropositivity. (C) % of CMV and EBV combined seropositivity.

Similar articles

Cited by

References

    1. van Stijn-Bringas Dimitriades D, Planken RN, Groenink M, Streekstra GJ, Kuijpers TW, Kuipers IM. Coronary artery assessment in Kawasaki disease with dual-source CT angiography to uncover vascular pathology. Eur Radiol. (2019). 10.1007/s00330-019-06367-6 - DOI - PMC - PubMed
    1. McCrindle BW, Manlhiot C, Newburger JW, Harahsheh AS, Giglia TM, Dallaire F, et al. . Medium-term complications associated with coronary artery aneurysms after kawasaki disease: a study from the international kawasaki disease registry. J Am Heart Assoc. (2020) 9:e016440. 10.1161/jaha.119.016440 - DOI - PMC - PubMed
    1. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. (1984) 2:1055–8. 10.1016/S0140-6736(84)91504-6 - DOI - PubMed
    1. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. (1997) 131:888–93. 10.1016/S0022-3476(97)70038-6 - DOI - PubMed
    1. Kuwabara M, Yashiro M, Ae R, Yanagawa H, Nakamura Y. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: the 22nd nationwide survey in Japan. Int J Cardiol. (2018) 269:334–8. 10.1016/j.ijcard.2018.07.092 - DOI - PubMed

LinkOut - more resources